- Record: found
- Abstract: not found
- Article: not found
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A Margolis ,
Juan Gonzalez-Garcia ,
Hans-Jürgen Stellbrink ,
Joseph J Eron ,
Yazdan Yazdanpanah ,
Daniel Podzamczer ,
Thomas Lutz ,
Jonathan B Angel ,
Gary J Richmond ,
Bonaventura Clotet ,
Felix Gutierrez ,
Louis Sloan ,
Marty St Clair ,
Miranda Murray ,
Susan L Ford ,
Joseph Mrus ,
Parul Patel ,
Herta Crauwels ,
Sandy K Griffith ,
Kenneth C Sutton ,
David Dorey ,
Kimberly Y Smith ,
Peter E Williams ,
William R Spreen
September 2017
September 2017
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Cabotegravir and rilpivirine are antiretroviral drugs in development as long-acting
injectable formulations. The LATTE-2 study evaluated long-acting cabotegravir plus
rilpivirine for maintenance of HIV-1 viral suppression through 96 weeks.